Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trialStephen A. Boorjian, Colin P. Dinney, Trinity J. Bivalacqua et al.|The Lancet Oncology|2020Cited by 459
Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized StudyNeal D. Shore, Colin P. Dinney, Stephen A. Boorjian et al.|Journal of Clinical Oncology|2017Cited by 175
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical TrialAnirban P. Mitra, Colin P. Dinney, Vikram M. Narayan et al.|European Urology|2021Cited by 24